What does ELITE stand for?

Early versus Late Intervention Trial with Estradiol. The name reflects the trial's central question: does the timing of estrogen initiation relative to menopause onset determine cardiovascular outcomes?

How is ELITE different from the Women's Health Initiative?

WHI enrolled older women (average age 63) and used conjugated equine estrogens plus medroxyprogesterone acetate. ELITE specifically stratified by years since menopause, used bioidentical oral estradiol with vaginal progesterone, and measured subclinical atherosclerosis rather than clinical events.

Did ELITE show that HRT prevents heart attacks?

No. ELITE showed that early-initiation estradiol slows carotid artery wall thickening. This is a surrogate marker, not a clinical event. No reduction in heart attacks or strokes was demonstrated because the trial was not designed or powered for that endpoint.

What dose of estradiol was used in the ELITE trial?

Oral 17β-estradiol at 1 mg per day, which is the standard FDA-approved dose for menopausal hormone therapy.

Who should consider starting HRT based on ELITE's findings?

Healthy women within 6 years of menopause who have vasomotor symptoms and no contraindications. The NAMS 2022 position statement supports this window for favorable cardiovascular risk-benefit.

Does ELITE apply to women using estrogen patches instead of pills?

ELITE tested only oral estradiol. Transdermal estrogen has a different metabolic profile. While many clinicians believe the timing hypothesis applies regardless of route, that has not been directly tested in a randomized trial of comparable design.

Why did the late-initiation group show no benefit?

Women ≥10 years past menopause likely have more established atherosclerosis and fewer functional vascular estrogen receptors. The protective biological pathway (ERα-mediated nitric oxide signaling) appears to require relatively healthy arterial tissue to function, as supported by preclinical primate studies.

What happened with coronary artery calcium scores in ELITE?

CAC scores showed no significant difference between estradiol and placebo in either timing group. This suggests estrogen's early vascular benefit may involve non-calcified plaque or arterial remodeling rather than calcium deposition specifically.

How long were women treated in the ELITE trial?

The median treatment duration was 5 years, with CIMT measurements taken every 6 months throughout the study period. The trial ran from 2005 to 2013 at a single center at USC.

Has any guideline changed because of ELITE?

Yes. Both the 2017 Endocrine Society guideline and the 2022 NAMS position statement cite ELITE when endorsing the timing hypothesis and recommending that early-postmenopausal women be considered for HRT.

ELITE Trial: A Plain-English Overview of What It Established

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for ELITE Trial: A Plain-English Overview of What It Established Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |-----------|--------| | N | 643 healthy postmenopausal women | | Intervention | Oral 17β-estradiol 1 mg/day (± vaginal progesterone) | | Comparator | Matching placebo | | Duration | Median 5 years of treatment | | Primary endpoint | Rate of change in carotid artery intima-media thickness (CIMT) | | Key result | Early-initiation group: significantly slower CIMT progression vs. placebo; late-initiation group: no significant difference |

The question ELITE set out to answer

By 2005, the Women's Health Initiative (WHI) had reported that combined HRT increased cardiovascular events. But critics noted that WHI participants averaged 63 years old, more than a decade past menopause. A growing body of animal and observational data suggested that estrogen protects arteries only when the vessel wall is still relatively healthy. Expose aged, already-diseased arteries to estrogen, and you might get the opposite effect.

This concept became known as the "timing hypothesis." The ELITE trial (Early versus Late Intervention Trial with Estradiol) was specifically designed to test it in humans with a randomized, controlled methodology and a direct vascular imaging endpoint.

Who was enrolled

ELITE recruited 643 healthy postmenopausal women at the University of Southern California between 2005 and 2013. Participants were stratified into two cohorts based on time since menopause:

Early postmenopause: <6 years since final menstrual period (n = 271)
Late postmenopause: ≥10 years since final menstrual period (n = 372)

Women with pre-existing cardiovascular disease, diabetes, or uncontrolled hypertension were excluded. This is a critical design choice: ELITE tested primary prevention in relatively healthy women, not treatment for established disease. The published protocol specified these inclusion criteria to isolate the effect of timing rather than background disease burden.

What participants received

Within each time-since-menopause stratum, women were randomized to:

Oral 17β-estradiol 1 mg/day, or
Placebo

Women with a uterus also received micronized vaginal progesterone (45 mg gel) for 10 days per month to protect the endometrium. This route of progesterone administration was chosen to minimize systemic progestogen exposure, which had been implicated in the cardiovascular harms seen in WHI's combined-therapy arm. The FDA label for estradiol confirms the standard 1 mg oral dose used in ELITE for menopausal hormone therapy.

How atherosclerosis was measured

The primary endpoint was the rate of change in carotid artery intima-media thickness (CIMT), measured by B-mode ultrasonography every 6 months. CIMT is a validated surrogate for subclinical atherosclerosis. Thicker walls indicate more plaque buildup. The rate of increase over time tells you how fast the disease is progressing.

Secondary endpoints included coronary artery calcium (CAC) scores measured by cardiac CT at baseline and trial end. CAC provides a complementary view of calcified plaque burden in the coronary vessels specifically, as described in the original ELITE publication.

Results: what the numbers showed

The primary analysis demonstrated a statistically significant interaction between treatment assignment and time since menopause (p = 0.007 for the interaction term), confirming that timing matters.

Early postmenopause group (<6 years)

| Measure | Estradiol | Placebo | Difference | |---------|-----------|---------|------------| | CIMT progression rate (mm/year) | 0.0044 | 0.0078 | −0.0034 (p = 0.008) |

Women who started estradiol early had roughly half the rate of carotid wall thickening compared to placebo.

Late postmenopause group (≥10 years)

| Measure | Estradiol | Placebo | Difference | |---------|-----------|---------|------------| | CIMT progression rate (mm/year) | 0.0088 | 0.0088 | 0.0000 (p = 0.95) |

Estradiol made no measurable difference in women who were a decade or more past menopause.

Coronary artery calcium

CAC scores did not differ significantly between estradiol and placebo in either group. This null finding on the secondary endpoint is worth noting. CIMT and CAC measure different aspects of vascular disease, and the discordance suggests that estrogen's early benefit may relate more to arterial wall remodeling than to calcified plaque deposits. The 2017 Endocrine Society guidelines reference this nuance when discussing surrogate endpoints.

Why the timing matters biologically

Estrogen receptors (ERα) are abundant in healthy vascular endothelium. When arteries are young and relatively free of atherosclerotic plaque, estrogen binding to these receptors promotes nitric oxide production, reduces inflammation, and inhibits smooth muscle proliferation. Once atherosclerosis is established, the receptor population changes. Foam cells and fibrous cap tissue express fewer functional ERα, so the protective signaling pathway is diminished.

ELITE's results are consistent with earlier primate data from the Clarkson lab showing that estrogen prevented coronary atherosclerosis in ovariectomized monkeys only when started immediately, not after a prolonged estrogen-free interval. The human data now confirmed what the animal models predicted.

Limitations the authors acknowledged

The ELITE investigators were transparent about several constraints:

Surrogate endpoint, not clinical events. CIMT progression is a validated marker but not a hard clinical outcome like myocardial infarction or stroke. The trial was not powered to detect differences in heart attacks or deaths.
Single-site recruitment. All participants came from the Los Angeles area through USC, limiting generalizability to other populations.
Relatively short duration. A median of 5 years may not capture longer-term risks such as breast cancer, which the WHI identified after longer follow-up periods.
No conjugated equine estrogen arm. ELITE used oral 17β-estradiol, the bioidentical form. Results may not apply to other estrogen formulations, particularly conjugated equine estrogens used in WHI.
Progesterone route. Vaginal progesterone does not perfectly replicate the systemic progestogen exposure most women using oral combined HRT receive.

How ELITE changed clinical practice

Before ELITE, many clinicians avoided prescribing HRT to any postmenopausal woman for cardiovascular reasons, citing WHI. After ELITE's 2016 NEJM publication, professional society guidelines shifted.

The 2022 North American Menopause Society (NAMS) position statement now explicitly endorses the timing hypothesis: for women under 60 or within 10 years of menopause, the benefit-risk profile of HRT favors treatment when vasomotor symptoms are present. ELITE is cited as a key piece of evidence supporting that window.

The 2017 Endocrine Society clinical practice guideline similarly recommends that transdermal or oral estradiol be considered for symptomatic women in early menopause and acknowledges ELITE's vascular findings.

In practice, this means a 52-year-old woman who went through menopause at 50 and has hot flashes can discuss HRT with her physician without the blanket cardiovascular concern that dominated post-WHI counseling. A 68-year-old woman 15 years past menopause, however, should not start HRT expecting heart protection.

What ELITE did not prove

It did not prove that HRT prevents heart attacks. It proved that early-initiation estradiol slows one measurable marker of atherosclerosis progression. The gap between slowing CIMT thickening and preventing a clinical event is real and important. Larger event-driven trials would be needed to confirm that the CIMT benefit translates to fewer cardiovascular events, and no such trial is currently underway.

It also did not address transdermal estradiol, which has a different metabolic profile (no first-pass hepatic effect, lower clotting factor impact). Some clinicians extrapolate ELITE's findings to transdermal routes, but that remains an assumption rather than proven fact, as noted in the NAMS 2022 statement.

Frequently asked questions

›

References

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. PubMed
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333. PubMed
Clarkson TB, Appt SE. Controversies about HRT: lessons from monkey models. Maturitas. 2005;51(1):64-74. PubMed
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. PubMed
FDA Label: Estradiol tablets. U.S. Food and Drug Administration. AccessData